PAZ PHARMACEUTICALS

Biotech · Private

Small-molecule inhibitor of GPR55 and biased agonist of β2-adrenergic receptor for pancreatic cancer

Grants
$385K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer$385,139
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2442PRECISION QUANTOMICS INC——
2443RHINO THERAPEUTICS INC——
2444INTERVAL THERAPEUTICS LLC——
2445PAZ PHARMACEUTICALS——
2446Ribometrix LLC—$18M
2447Spark2Flame, Inc——
2448Biohaven Pharmaceutical Holding Co Ltd.—$40M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.